Furthermore, all PD-L1-positive squamous cell carcinomas co-express TIM-3 and Gal-9, suggesting the potential of combination therapies involving immune checkpoint inhibitors for future cervical cancer treatment. This evidence concerns the gene HAVCR2 and squamous cell carcinoma.